Ben-Ami H, Nagachandran P, Mendelson A, Edoute Y
Department of Internal Medicine C, Rambam Medical Center, and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa.
Arch Intern Med. 1999 Feb 8;159(3):281-4. doi: 10.1001/archinte.159.3.281.
Hypoglycemic coma is a continuous threat for diabetic patients treated with insulin and/or oral hypoglycemic agents; it may be associated with substantial morbidity and mortality.
We retrospectively reviewed our clinical experience with drug-induced hypoglycemic coma during a 7-year period.
The study consisted of 102 patients and included 61 females and 41 males. The median age was 72 years. Ninety-two patients suffered from type 2 diabetes mellitus; 10 patients had type 1 diabetes mellitus. The median lowest blood glucose level was 1.77 mmol/L (32 mg/dL). Drug-induced hypoglycemic coma occurred in 99 patients out of the hospital, while 3 patients developed it during hospitalization. Drug-induced hypoglycemic coma occurred in patients undergoing treatment with insulin, glyburide, and combined therapy with insulin and glyburide, insulin and metformin, or glyburide and metformin. Ninety-three patients had at least 1 of the following risk factors: age older than 60 years, renal dysfunction, decreased intake of energy, and infection. Fourteen patients concomitantly received drugs that potentiated hypoglycemia. Forty patients responded to treatment within the first 12 hours, while 62 patients had protracted hypoglycemia of 12 to 72 hours' duration. Morbidity included physical injuries in 7 patients, myocardial ischemia in 2 patients, and stroke in 1 patient. Death occurred in 5 patients.
Hypoglycemic coma is a serious and not an uncommon problem among elderly patients with diabetes mellitus and treated with insulin and/or oral hypoglycemic drugs. Risk factors contribute substantially to the morbidity and mortality of patients with drug-induced hypoglycemic coma. Enhanced therapeutic monitoring may be warranted when hypoglycemic drugs are administered to an elderly patient with the above predisposing factors and potentiating drugs for hypoglycemia.
低血糖昏迷对接受胰岛素和/或口服降糖药治疗的糖尿病患者构成持续威胁;它可能与严重的发病率和死亡率相关。
我们回顾性分析了7年间药物性低血糖昏迷的临床经验。
该研究共纳入102例患者,其中女性61例,男性41例。中位年龄为72岁。92例患者患有2型糖尿病;10例患者患有1型糖尿病。最低血糖水平中位数为1.77 mmol/L(32 mg/dL)。99例患者在院外发生药物性低血糖昏迷,3例患者在住院期间发生。药物性低血糖昏迷发生在接受胰岛素、格列本脲治疗的患者,以及胰岛素与格列本脲、胰岛素与二甲双胍或格列本脲与二甲双胍联合治疗的患者中。93例患者至少有以下1项危险因素:年龄大于60岁、肾功能不全、能量摄入减少和感染。14例患者同时服用了增强低血糖作用的药物。40例患者在最初12小时内对治疗有反应,62例患者发生了持续12至72小时的低血糖。并发症包括7例身体损伤、2例心肌缺血和1例中风。5例患者死亡。
低血糖昏迷在老年糖尿病患者且接受胰岛素和/或口服降糖药治疗中是一个严重且并非罕见的问题。危险因素在很大程度上导致了药物性低血糖昏迷患者的发病率和死亡率。当对有上述易感因素的老年患者使用降糖药物以及增强低血糖作用的药物时,可能需要加强治疗监测。